Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

Ovidio Fernández Calvo, José Muñoz Iglesias, Estephany Abou Jokh Casas, Aura Molina-Díaz, Urbano Anido Herranz, Javier Casas Nebra, Lucía García-Bernardo, Sara Martínez-Breijo, Martín Lázaro-Quintela, Gloria Muñiz-García, Sergio Vázquez-Estevez
{"title":"Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer","authors":"Ovidio Fernández Calvo, José Muñoz Iglesias, Estephany Abou Jokh Casas, Aura Molina-Díaz, Urbano Anido Herranz, Javier Casas Nebra, Lucía García-Bernardo, Sara Martínez-Breijo, Martín Lázaro-Quintela, Gloria Muñiz-García, Sergio Vázquez-Estevez","doi":"10.1007/s12094-024-03662-7","DOIUrl":null,"url":null,"abstract":"<p>Theragnostic is a type of precision medicine that uses molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. In recent years, it has gained significant importance to treat neuroendocrine tumors and is currently being used in prostate cancer. Various radiopharmaceuticals have emerged for diagnosing and detecting lesions showing prostate-specific membrane antigen (PSMA) positivity on the Positron emission tomography/computed tomography scan, being the most widely used labeled with [<sup>68</sup>Ga] and [<sup>18</sup>F]. Its use as therapy in prostate cancer (PC) has been assessed in the VISION, TheraP, and PSMAfore clinical trials conducted with the radioligand [<sup>177</sup>Lu]Lu-PSMA-617, demonstrating significant antitumor activity. The aim of this article is to present practical recommendations, based on current available scientific evidence and on a multidisciplinary consensus, for the diagnosis and treatment with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with PC.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"22 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12094-024-03662-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Theragnostic is a type of precision medicine that uses molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. In recent years, it has gained significant importance to treat neuroendocrine tumors and is currently being used in prostate cancer. Various radiopharmaceuticals have emerged for diagnosing and detecting lesions showing prostate-specific membrane antigen (PSMA) positivity on the Positron emission tomography/computed tomography scan, being the most widely used labeled with [68Ga] and [18F]. Its use as therapy in prostate cancer (PC) has been assessed in the VISION, TheraP, and PSMAfore clinical trials conducted with the radioligand [177Lu]Lu-PSMA-617, demonstrating significant antitumor activity. The aim of this article is to present practical recommendations, based on current available scientific evidence and on a multidisciplinary consensus, for the diagnosis and treatment with [177Lu]Lu-PSMA-617 in patients with PC.

Abstract Image

加利西亚肿瘤学会和加利西亚核医学学会关于在前列腺癌中使用 177Lu-PSMA-617 放射性配体疗法的建议
热诊断是一种利用与放射性同位素相连的分子来诊断和治疗疾病的精准医学。近年来,它在治疗神经内分泌肿瘤方面发挥了重要作用,目前正被用于前列腺癌的治疗。正电子发射断层扫描/计算机断层扫描扫描显示前列腺特异性膜抗原(PSMA)阳性的病变诊断和检测出现了多种放射性药物,其中使用最广泛的是标记有[68Ga]和[18F]的药物。在使用放射性配体[177Lu]Lu-PSMA-617进行的VISION、TheraP和PSMAfore临床试验中,对其作为前列腺癌(PC)的治疗方法进行了评估,结果显示其具有显著的抗肿瘤活性。本文旨在根据现有科学证据和多学科共识,就 PC 患者使用[177Lu]Lu-PSMA-617 进行诊断和治疗提出实用建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信